---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39330969.md"
description: "Don't compare small molecules with large molecules, small molecule drugs have low cost and fast production, as long as the effect is acceptable they can capture the low-income market. Additionally, Eli Lilly's large molecule efficacy currently leads Novo Nordisk, and the oral large molecule launch is slower than Novo Nordisk. Although I'm a shareholder of NVO, I have to say this chart is unfair to LLY."
datetime: "2026-03-18T07:26:12.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39330969.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39330969.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39330969.md)
author: "[艾萨克·牛顿](https://longbridge.com/en/profiles/15057684.md)"
---

# Don't compare small molecules with large molecules…


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)